Login to Your Account

AMO Pharma advancing ultra-rare program on back of phase IIb data

By Nuala Moran
Staff Writer

Tuesday, April 10, 2018

LONDON – AMO Pharma Ltd. is laying plans, both clinical and financial, for a phase III study of its lead program, AMO-02 (tideglusib), after reporting final data from a phase IIb proof-of-concept trial in the treatment of congenital and childhood onset myotonic dystrophy type 1.

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription